MRC1 and acute myeloid leukemia: Interestingly, mouse studies showed that MMR-deficient cells have a survival advantage over wild-type cells when exposed to temozolomide [157], a methylating agent used to treat certain brain tumors and known to be associated with an increased risk for t-MDS/AML development [157,158,159].